Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05769634 · ClinicalTrials.gov registry record · NA

Electrophysiologic Studies of Cognition in Epilepsy Patients

A NA study of Drug Resistant Epilepsy, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT05769634 is a NA study of Drug Resistant Epilepsy that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 20 participants, below the 33-participant average among 6 other Drug Resistant Epilepsy trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05769634, a NA study of Drug Resistant Epilepsy, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

Interoception, or sensation from inside the body, is involved in a variety of clinical symptoms, such as tics, compulsions and negative mood. This study uses invasive recordings of brain activity and brain stimulation to better understand basic neural mechanisms of interoception and related behaviors. Outcomes of this study provide critical tools for future investigation into clinical symptoms that emerge from abnormal interoception.

Conditions Studied

Interventions

  • BEHAVIORAL Stereoelectroencephalography

Study Locations (1)

New York

  • Mount Sinai West - New York

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2022-08-10
Est. Completion 2024-05-28
Phase NA

What the Registry Record Tells You About NCT05769634

The ClinicalTrials.gov registry entry for NCT05769634 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 33-participant average among 6 other Drug Resistant Epilepsy trials with a reported enrollment target (39% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Drug Resistant Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Stereoelectroencephalography is the first listed.

NCT05769634 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05769634 about?

NCT05769634 is a clinical study titled "Electrophysiologic Studies of Cognition in Epilepsy Patients". Interoception, or sensation from inside the body, is involved in a variety of clinical symptoms, such as tics, compulsions and negative mood. This study uses invasive recordings of brain activity and brain stimulation to better understand basic neural mechanisms of interoception and related behavior...

What is the current status of trial NCT05769634?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2022-08-10. Estimated completion is 2024-05-28.

What conditions does trial NCT05769634 study?

This clinical trial studies the following conditions: Drug Resistant Epilepsy.

What interventions are being tested in trial NCT05769634?

The interventions under investigation include: Stereoelectroencephalography (BEHAVIORAL).

Who is sponsoring clinical trial NCT05769634?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05769634 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Drug Resistant Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.